Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET
Company Participants
Jenny Kobin - Investor Relations
George Lasezkay - President and Chief Executive Officer
Charles Deignan - Chief Financial Officer
Conference Call Participants
Serge Belanger - Needham & Company
Annabel Samimy - Stifel
Andreas Argyrides - Wedbush Securities
Yi Chen - H.C. Wainwright
Operator
Good day and thank you for standing by. Welcome to the Clearside Biomedical First Quarter 2023 Financial Results and Corporate Update Call. At this time all participants are in a listen-only mode. After the speakers' presentation there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your speaker today, Jenny Kobin, Clearside’s Investor Relations.
Jenny Kobin
Good morning, everyone and thank you for joining us on the call today. Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2022, and our other SEC filings available on our website.
In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.
On today's call, we have George Lasezkay, our Chief Executive Officer and Charles Deignan, our Chief Financial Officer. After formal remarks, we will open the call for your questions.
I would now like to turn the call over to George.
George Lasezkay
Thank you, Jenny. We delivered a productive start to 2023 as we execute on our near-term plan to advance our lead asset, CLS-AX an investigational proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a highly potent tyrosine kinase inhibitor that achieves Pan VEGF blockades directly inhibiting. VEGF receptors, one, two and three with high potency and specificity.
We believe this broad VEGF blockade may have advantages over existing therapies for retinal diseases by acting at a different level of the angiogenesis cascade. Suprachoroidal injection of our proprietary CLS -AX suspension delivers Axitinib directly to the site of disease, and has demonstrated signs of biological effect and the potential for extended duration of therapy in our Phase 1, 2a away, since clinical trial in wet AMD.